After over a decade of development, two major clinical trials and three FDA advisory panels, Boston Scientific Corp.’s Watchman is finally set to reach the U.S. market. FDA approved the PMA for the left-atrial appendage closure device to prevent stroke in some patients with atrial fibrillation on March 13.
FDA and its advisors reviewing the device's data over the years struggled to identify exactly which patients it benefits. But the agency ultimately approved Watchman for reducing the risk of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?